Next Article in Journal
Longitudinal Predictors of Self-Regulation at School Entry: Findings from the All Our Families Cohort
Next Article in Special Issue
Safety and Dose-Dependent Effects of Echinacea for the Treatment of Acute Cold Episodes in Children: A Multicenter, Randomized, Open-Label Clinical Trial
Previous Article in Journal
Communicating with Youth about Pain: Developmental Considerations
Article

The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid

Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Children’s Hospital, Daegu 41404, Korea
*
Author to whom correspondence should be addressed.
Received: 10 September 2020 / Revised: 7 October 2020 / Accepted: 14 October 2020 / Published: 16 October 2020
(This article belongs to the Special Issue Advances in Pediatric Infection and Immunity)
Background: Acetylsalicylic acid (ASA) is part of the recommended treatment of Kawasaki disease (KD). Controversies remain regarding the optimal dose of ASA. We aimed to evaluate the impact of different doses of ASA on inflammation control while minimizing adverse effects in the acute phase treatment of KD. Methods: The enrolled 323 patients with KD were divided into three groups according to ASA dose: moderate-dose (30–50 mg/kg/day), high-dose (80–100 mg/kg/day), and non-ASA. Results: High-dose ASA group showed a significantly shorter duration of fever from the start of treatment to remission than other groups. Baseline level and delta score of interleukin (IL)-1, IL-6, IL-10, tumor necrosis factor-α, and transforming growth factor β were not statistically different among the groups. The number of patients who received additional treatments in the non-ASA group was more than other groups. Coronary artery dilatation was not significantly different among the groups. One patient with high-dose ASA was diagnosed with Reye syndrome. Conclusion: Different doses of ASA did not show any differences in changes of inflammatory bio-makers and cytokines. However, high-dose ASA showed occurrence of Reye syndrome, and non-ASA showed intravenous immunoglobulin refractoriness. We suggest that moderate-dose ASA may be beneficial for the treatment of patients in the acute phase of KD. View Full-Text
Keywords: acetylsalicylic acid; coronary artery; fever; Kawasaki disease acetylsalicylic acid; coronary artery; fever; Kawasaki disease
Show Figures

Figure 1

MDPI and ACS Style

Kwon, J.E.; Roh, D.E.; Kim, Y.H. The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid. Children 2020, 7, 185. https://0-doi-org.brum.beds.ac.uk/10.3390/children7100185

AMA Style

Kwon JE, Roh DE, Kim YH. The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid. Children. 2020; 7(10):185. https://0-doi-org.brum.beds.ac.uk/10.3390/children7100185

Chicago/Turabian Style

Kwon, Jung E., Da E. Roh, and Yeo H. Kim 2020. "The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid" Children 7, no. 10: 185. https://0-doi-org.brum.beds.ac.uk/10.3390/children7100185

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop